Viewpoint News & Awards

Viewpoint CSO “Spotlight Speaker” at World Molecular Imaging Congress

September 15, 2017 (Philadelphia, PA, USA) – Viewpoint Chief Science Officer Michael Schultz PhD was recently invited to speak at a “Spotlight Session – Advancing Drug Discovery with Molecular Imaging” at the World Molecular Imaging Congress. The conference Spotlight Sessions are designed to give attendees perspectives on current issues in molecular imaging. Dr. Schultz was invited to present his perspectives on the key role that University start-ups and small biotech companies play in advancing molecular imaging for drug development. “It is very exciting for Viewpoint to be recognized by the World Molecular Imaging Society as a successful company,” said Dr. Schultz. “It was a remarkable session with perspectives ranging from large Pharma to contract research organizations.  I was delighted to take part.”

Viewpoint Awarded $2 Million NCI Contract

September 8, 2017 (Coralville, IA) – Viewpoint Molecular Targeting, LLC, a University of Iowa start-up pharmaceutical company that has developed a novel therapy and companion diagnostic for metastatic melanoma, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) Contract Award valued at $2 million from the National Cancer Institute (NCI) to support pre-clinical studies of its lead product, VMT-01.

The company has successfully secured $900K in previously awarded Phase I SBIR grants and contracts. “We value the NCI’s continued recognition of the importance of our products and its support of our development program,” said Edwin Sagastume, Viewpoint’s lead engineer and a University of Iowa graduate. “These funds will accelerate our product development helping us bring our product forward into clinical trials.”

“This award is an excellent next step in advancing Viewpoint’s new therapy to the clinical stage,” said Viewpoint’s Chief Science Officer Michael Schultz. “We could not be more excited about our progress.”

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting develops therapies and diagnostics for cancer, with a focus on metastatic melanoma. It’s lead product, VMT-01, is an injectable radiopharmaceutical. The product can be used to determine the location and extent of cancerous tumors in the body and then can be used again to direct a lethal dose of radiation precisely to cancer cells in the body. This represents a new class of drugs called theranostics.

Viewpoint has successfully secured over $3.2 million through NIH SBIR grants, Iowa Economic Development Authority Demonstration Funds, Innovation Iowa Corporation Matching Funds, and contracts to pharmaceutical industry partners. The company aims to begin clinical trials for its lead product within two years and has other products in the development pipeline.

About NIH SBIR Program

The NIH SBIR program funds early stage small businesses that are seeking to commercialize innovative biomedical technologies. This competitive program helps small business participate in federal research and development to develop life-saving technologies and create jobs.

See more: UIHC

Viewpoint’s products are currently under development and therefore not approved by the FDA.

Viewpoint Wins Iowa SBIR Showcase Phase II Pitch Competition

September 6, 2017 (IOWA CITY, IA) – Viewpoint Molecular Targeting LLC, a University of Iowa spin-out company developing therapies and diagnostics for metastatic melanoma, recently placed first at the Iowa SBIR Showcase (Virtual SBIR Road Tour) pitch competition.

The company won first place in the Phase II Pitch competition receiving a prize of $10,000. Viewpoint faced stiff competition as they competed against seven other companies whom have previously been awarded a Phase II Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) award.

According to the SBIR Road Tour, “The Iowa SBIR Showcase is part of a national outreach effort to convey the technology funding opportunity provided through the SBIR and STTR programs. The SBIR/STTR programs annually provide $2.5 billion in funding to small advanced technology firms to spur new technological discoveries and facilitate the commercialization of innovations.”

The showcase also provided the company an opportunity for one-on-one virtual meetings with federal agencies such as the National Institutes of Health, National Science Foundation, the Department of Energy, as well as others. Additionally, the event offered networking opportunities to connect directly with potential investors, partners, and mentors.

“I’m thrilled that the judges thought we were deserving of this award”, said Dr. Frances Johnson, Viewpoint’s Chief Medical Officer. “These kind of business competitions inject energy into the business development process in ways that government grants and contracts cannot. They also provide a unique opportunity to meet personally with potential investors.”

IMG_0979

Iowa Innovation Corporation President and CEO Kirk Bjorland, Viewpoint co-founder and Chief Science Officer Dr. Michael Schultz, Viewpoint Engineer Edwin Sagastume, Viewpoint co-founder and Chief Medical Officer Dr. Frances Johnson, and Iowa Innovation Corporation Statewide SBIR/STTR Program Coordinator Jordan Hobfoll at the Iowa SBIR Showcase.

See more: UI Ventures, SBIR Road TourUIHC

Viewpoint’s products are currently under development and therefore not approved by the FDA.

Viewpoint selected by NCI to participate in I-Corps commercialization accelerator program

December 20, 2016 (Coralville, IA) – Viewpoint Molecular Targeting, LLC has been selected by the National Cancer Institute (NCI) to participate in the business accelerator program I-Corps in 2017.

The I-Corps program was developed by the National Science Foundation and adopted by select NIH institutes, including the NCI. The program helps SBIR funded companies accelerate the development and commercialization of new products and services that benefit society. This is achieved through an 8-week training program designed to provide scientists real world, hands-on entrepreneurial training, facilitated by experts in the biotech sector. Participants are selected by a competitive application process to receive grant support for the entrepreneurial training, mentorship, and collaborations that will assist them in translating research ideas into market ready products. The program kicks off with a 3-day workshop in Boston (MA) in early February. “This is an intense program that will no doubt help us to validate our business model assumptions and accelerate Viewpoint’s growth.” Says Viewpoint CEO Heyward Coleman. “We are geared up for an enthusiastic participation”.

Viewpoint, located in the UI BioVentures Center (Coralville, IA), is developing pharmaceutical drugs for therapy and diagnostic imaging of cancer, with a focus on metastatic melanoma. Viewpoint has secured over $1.2M in external funding; more than half of this amount has come from NIH SBIR grants and contracts. The company is poised to begin clinical testing for its lead product and has other products in the development pipeline.

“Our technology has the potential to save lives” says Co-founder and Chief Medical Officer Frances Johnson. “The NCI’s selection of Viewpoint to participate in the I-Corps program validates that potential and gives us another great opportunity to make targeted radiotherapy for melanoma a reality.”

See more: Viewpoint, I-Corps

Twitter: @Viewpoint_MT

“Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R43CA203430. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”
Viewpoint’s products are currently under development and therefore not approved by the FDA. 

Viewpoint Founders Meet with Legislators to Promote Biomedical Startups

September 20, 2016 – Washington, DC – Viewpoint Molecular Targeting, LLC founders met with Iowa legislators at the National Council on Entrepreneurial Tech Transfer (NCET2) National Demo Day.  The purpose was to educate them on the key role university based biomedical startups play in creating high value jobs and in improving national economic and social competitiveness.

NCET2 estimates that over 800 startups are created in universities annually. Viewpoint was selected as one of 35 “Best University Startups 2016” by NCET2 to present to legislators, corporates, venture groups and angels to discover, review, partner with and fund university startups.

Company founders described what helps drive the advancement of biomedical based startup companies like Viewpoint. They highlighted how university technology transfer offices facilitate the commercialization of important scientific discoveries by protecting intellectual property and licensing it. Additional programs like the University of Iowa (UI) John Pappajohn Entrepreneurial Center’s Venture School provide valuable guidance to faculty entrepreneurs throughout the startup process to increase startup success.

Additionally, Viewpoint emphasized the vital role government programs play in technology development leading to job creation and nationwide economic success. These include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs that cultivate scientific excellence and technological innovation, focused on American priorities, by awarding competitive federal research grants. Grants help provide the funding necessary during critical startup and development stages, when private equity investment is difficult to obtain. The founders encouraged continued appropriations at levels necessary to ensure the commercialization of emerging biomedical technology.

Government programs not only provide grant support to biomedical startups, but also provide access to scarce materials vital for conducting medical research. Viewpoint’s founders highlighted the importance of the Department of Energy Radioisotope Program, which makes medically pertinent isotopes available for use by biomedical startups. Many of these materials are repurposed from former nuclear weapons programs, turning waste products into useful biomedical imaging and cancer treatment tools for the future.

Viewpoint hopes collaboration with legislators will help expedite biomedical startups’ technological developments, in turn, advancing human health and national economic success.

See more: Cedar Rapids GazetteUI Internal Med Making The RoundsNCET2 Demo Day

Demo Day

Viewpoint co-founder and Chief Medical Officer Dr. Frances L Johnson, left, Senator Joni Ernst of Iowa, center, and Viewpoint co-founder and Chief Science Officer Dr. Michael K Schultz, at U.S. Capitol.

Viewpoint’s products are currently under development and therefore not approved by the FDA. 

Viewpoint identified in “Best University Startups 2016” in the United States

August 31, 2016 (Coralville, IA) – Viewpoint Molecular Targeting, LLC has been identified as one of the “Best University Startups 2016” by the National Council on Entrepreneurial Tech Transfer (NCET2) and was one of 35 companies invited to present at the NCET2 National Demo Day in Washington, D.C. on September 20th.

NCET2 University Startups Demo Day highlights universities’ success in constructing cross-campus “innovation ecosystems”. It is estimated that over 800 startups are created in universities annually and 200 of those companies were considered for this event. “Viewpoint clearly stands out as having an exceptional blend of innovative biomedical technology and business leadership that will take the company to the next level” says NCET2 Associate Director Ria Ancheta-Adrias.  “The team was an obvious choice for a Best University Startup 2016 designation”.

Viewpoint has been selected based on the commercialization potential of its technology; recent successes in securing Small Business Innovation Research grant funding from the National Institutes of Health; and strength of its business plan for growing the company. “We are absolutely delighted” says Co founder and Chief Science Officer Michael K Schultz. “The selection to the list of Best Startups is further evidence that we are making sound business decisions and are being recognized for it.”

Viewpoint Molecular Targeting is developing pharmaceutical drugs for diagnostic imagining and therapy for cancer, with a focus on metastatic melanoma, and is located in the UI BioVentures Center. Viewpoint has successfully secured over $1.2Mln through NIH SBIR grants; Iowa Economic Development Authority Demonstration Funds; Innovation Iowa Corporation Matching Funds; and contracts to pharmaceutical industry partners. The company is aiming to begin clinical trials for its lead product and has other products in the development pipeline.

“Our technology has the potential to save lives” says Co-founder and Chief Medical Officer Frances L Johnson “The selection by NCET2 to present at Demo Day, gives us another great opportunity to make that a reality and we’re excited.”

“Viewpoint continues to make exceptional progress in building a company that is positioned for growth” says Paul Dymerski, Director for New Ventures at the University of Research Foundation

See more: OVPR-EDIowa Biotech AssociationUI Health Care

 

usdd_badge

Viewpoint’s products are currently under development and therefore not approved by the FDA. 

Viewpoint Wins Innovation Showcase Top Company Award

April 4, 2016 – VIEWPOINT MOLECULAR TARGETING RECEIVES TOP COMPANY AWARD IN PARTNERING FOR GROWTH BIOTECH INNOVATION SHOWCASE


DES MOINES, IA (USA) –
Iowa Biotechnology Association (IowaBio) Executive Director Joe Hrdlicka said today Viewpoint Molecular Targeting, of Coralville, was awarded the top company award at this year’s Partnering For Growth Biotech Innovation Showcase.

Viewpoint Molecular Targeting is a startup pharmaceutical company that develops therapies and diagnostics for cancer – with a focus on metastatic melanoma. The lead product VMT-MCR1 is a combination diagnostic-therapeutic radiopharmaceutical, a technology platform referred to as a “theranostic”. The product can be used to precisely determine the location and extent of cancerous tumors in the body and then be used to direct a lethal dose of radiation precisely to cancer cells in the body.

Hrdlicka said this event is the result of industry leaders and investors seeking to establish a gathering of innovators, inventors and investors to collaborate on their work specific to the field of biotechnology. The Showcase provides a forum for biotech leaders in Iowa and beyond to present their innovations to potential investors in Iowa and beyond.  He said the company was presented with a $5,000 check in a presentation following the event.

“Our expert panel felt Viewpoint made the most compelling case for best company,” Hrdlicka said. “We had 12 companies from around the country. Viewpoint’s work exemplifies Iowa’s leadership position in bioscience.”

“The Showcase has been an outstanding experience for Viewpoint and we’re honored and energized by the top honors selection from an exceptional group of exciting up and coming companies,” said Dr. Michael Schultz, Viewpoint’s chief science officer.  “The experience has helped us to better communicate our mission and our potential value and seeing the others present has been inspiring!”

More: IowaBio

Contact: Joe Hrdlicka (515) 327-9156-office (515) 250-9798-mobile joe@iowabio.org

IowaBio’s Partnering For Growth forum is the state’s “biotechnology summit” targeted to senior leaders in biotech who have funding, human resources, issues management, business development and research in their areas of responsibility. The event also attracts public leaders who lead programs assisting the biotech sector from a funding, regulatory or economic development perspective. Partnering For Growth features a series of educational presentations, track sessions and networking activities aimed at sharing best practices and opportunities for collaboration within the industry in addition to the Biotech Innovation Showcase.

Viewpoint’s products are currently under development and therefore not approved by the FDA.

Viewpoint Rings in New Year – 4th SBIR ($300,000) Awarded by NIH

January 7, 2016 (Coralville, IA) – Viewpoint is pleased to announce it has secured a fourth consecutive collaborative Small Business Innovation Research (SBIR) Grant ($300,000), awarded by the National Institutes of Health. The funding, which brings total funding awarded to the company in the last 24 months over $1.2M, provides support for exciting new product development that advances its novel image-guided therapy for metastatic melanoma toward early phase clinical trials. “It is exciting to see that our peers are recognizing the potential of our image-guided therapy approach,” states Frances Johnson MD, Chief Medical Officer of Viewpoint. “This award is particularly exciting because it provides support for new ideas that expand the potential of our portfolio”.

“We have some exciting new ideas about image-guided therapy that this funding will allow us to explore in detail,” says Michael Schultz, PhD, CSO of Viewpoint (also Associate Professor in the Departments of Radiology, Radiation Oncology, and Chemistry at University of Iowa). “We are excited about the momentum that we are experiencing and the potential that these new directions represent.”

Viewpoint’s products are currently under development and therefore not approved by the FDA.

Viewpoint Awarded $300,000 NCI Phase I SBIR

October 7, 2015 (Coralville, IA) – Viewpoint is pleased to announce it has secured a third consecutive collaborative Small Business Innovation Research (SBIR) Grant ($300,000), awarded by the National Institutes of Health. Viewpoint will focus on the development of its novel image-guided therapy for metastatic melanoma. “Viewpoint is excited about the momentum of its lead compound” states Frances Johnson MD, Chief Medical Officer of Viewpoint. “This award fuels our efforts in our initiatives”.

This contract with NIH is an exciting milestone for our company to bring our therapy platform one big step further toward metastatic melanoma patient care,” says Michael Schultz, PhD, CSO of Viewpoint (also Associate Professor in the Departments of Radiology, Radiation Oncology, and Chemistry at University of Iowa). “Our network of collaborators is paving the way toward clinical trials and commercialization of our new platform technologies.”

Viewpoint’s products are currently under development and therefore not approved by the FDA.

Viewpoint Advances to Top 10 in State Competition

Coralville, Iowa – Viewpoint Molecular Targeting has advanced to the third round in the John Pappajohn Iowa Entrepreneurial Business Plan Competition. Viewpoint is one of a total of 26 companies (out of the 44 entries) that were selected to advance to the second round in the statewide business plan competition. This advancement is on the heals of a series of successful proposals to the National Institutes of Health, the Iowa Economic Development Authority, and Innovation Iowa.

“We are delighted to have the opportunity to present in the next round of the competition,” says Viewpoint CSO Michael Schultz, “Success in the early rounds gives us confidence that our story looks good on paper. The final round gives us a chance to pitch our plan in person, which is great experience for our fundraising activities.”

More: Iowa JPECUNIBusiness Record

About Viewpoint

Viewpoint Molecular Targeting, LLC develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Our novel image-guided therapies enable a personalized approach to select patients that can benefit most and to optimize treatment planning for our targeted therapies. Our unique “theranostic” agents possess properties for both diagnostic imaging and therapy for cancer, personalizing the selection of patients and optimizing patient care.

Recent Posts